基因重组抗原受体(CAR)T细胞抗CD30是一种创新的治疗选择，已被用于治疗难治 / 复发（R / R）经典霍奇金淋巴瘤（CHL）的病例。目前有限数据可用于描述治疗后复发患者的CD30表达情况。这是第一项研究，显示在我们机构接受CAR T细胞治疗的R / R CHL患者（n = 5）中，CD30表达显著降低。尽管传统的免疫组化检测在所有案例（8/8）中均显示恶性细胞中的CD30表达降低，但酪氨酸放大检测和RNAScope原位杂交检测可分别检测出100％（n = 8/8）和75％（n = 3/4）的不同水平的CD30表达。因此，我们的研究结果证明恶性细胞仍然保留了某些CD30表达水平，这不仅具有生物学意义，而且对诊断也非常重要，因为CD30的检测对于确立CHL诊断是必不可少的。© 2023 John Wiley＆Sons Ltd。

Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients (n = 5) who underwent CAR T-cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% (n = 8/8) and 75% (n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.© 2023 John Wiley & Sons Ltd.